Article Sidebar
Article Details
The author(s) retain copyright on work published by AOSIS unless specified otherwise.
Licensing and publishing rights
Author(s) of work published by AOSIS are required to grant AOSIS the unlimited rights to publish the definitive work in any format, language and medium, for any lawful purpose. AOSIS requires journal authors to publish their work in open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
Read more here: http://creativecommons.org/licenses/by/4.0/.
The authors retain the non-exclusive right to do anything they wish with the published article(s), provided attribution is given to the applicable journal with details of the original publication, as set out in the official citation of the article published in the journal. The retained right specifically includes the right to post the article on the authors’ or their institution’s websites or in institutional repositories.
Previously published work may have been published under a different licence. We advise the community that if they would like to reuse the work to consult the applicable licence at article level.
Main Article Content
When to start antiretroviral therapy in infants and children
Abstract
seen in Africa and provided an impetus for advancing ART in children. Because of poor predictive value of CD4 counts in infancy and inability to predict risk of death or disease progression, we recommend initiating ART in all infants under a year of age. CD4 thresholds for initiating therapy decline as children become older. WHO stage 3 and 4 should trigger ART regardless of CD4 count. Over 5 years of age, a CD4 count <350/μl requires ART.
